Sutro Biopharma (STRO) Cash & Equivalents (2016 - 2026)
Sutro Biopharma (STRO) posted Cash & Equivalents of $58.1 million for Q4 2025, down 11.83% sequentially from $65.9 million in Q3 2025, and down 69.45% YoY from $190.3 million in Q4 2024.
Sutro Biopharma (STRO) Cash & Equivalents (2016 - 2026) Analysis & Trends
Sutro Biopharma has reported Cash & Equivalents for 10 years, with the latest figure at $58.1 million in Q4 2025.
- Quarterly Cash & Equivalents fell 69.45% year-over-year to $58.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58.1 million (down 69.45% YoY) and the FY2025 annual result came in at $58.1 million, down 69.45% from the prior year.
- Cash & Equivalents slipped to $58.1 million in Q4 2025 per STRO's latest filing, from $65.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $235.1 million in Q2 2023 and troughed at $28.9 million in Q1 2022.
- A 5-year average of $84.5 million and a median of $65.6 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2021 and 2022: Cash & Equivalents plunged 85.25% in 2021, then soared 215.17% in 2022.
- Over 5 years, Cash & Equivalents stood at $30.4 million in 2021, then soared by 55.37% to $47.3 million in 2022, then soared by 46.59% to $69.3 million in 2023, then jumped by 174.74% to $190.3 million in 2024, then slumped by 69.45% to $58.1 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $58.1 million, $65.9 million, and $64.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 54.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.34 Mn |
| Dec 31, 2025 | 58.13 Mn |
| Sep 30, 2025 | 65.93 Mn |
| Jun 30, 2025 | 64.03 Mn |
| Mar 31, 2025 | 106.23 Mn |
| Dec 31, 2024 | 190.30 Mn |
| Sep 30, 2024 | 174.58 Mn |
| Jun 30, 2024 | 90.79 Mn |
| Mar 31, 2024 | 65.22 Mn |
| Dec 31, 2023 | 69.27 Mn |
| Sep 30, 2023 | 81.83 Mn |
| Jun 30, 2023 | 235.10 Mn |
| Mar 31, 2023 | 62.47 Mn |
| Dec 31, 2022 | 47.25 Mn |
| Sep 30, 2022 | 96.78 Mn |
| Jun 30, 2022 | 79.12 Mn |
| Mar 31, 2022 | 28.90 Mn |
| Dec 31, 2021 | 30.41 Mn |
| Sep 30, 2021 | 30.71 Mn |
| Jun 30, 2021 | 56.39 Mn |